MedTrace Logo

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-11-13

No results posted yet for this study

Summary

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.

The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Sponsors & Collaborators

  • Telios Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2024-12-10
Completion
2024-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686472 on ClinicalTrials.gov